Exagen Inc. AVISE Testing Now Covered and In-Network with TRICARE East
Exagen Inc. (Nasdaq: XGN) has announced that its AVISE test offerings will be available as a contracted service through TRICARE East, managed by Humana Military. This agreement will make AVISE tests accessible to around 6 million beneficiaries, aiming to enhance the diagnosis and monitoring of autoimmune diseases such as lupus. CEO Ron Rocca emphasized the importance of these tests in supporting rheumatologists to improve patient care.
As Exagen seeks to revolutionize the care for autoimmune disease patients, the company expects to gain greater market acceptance of its innovative testing products.
- AVISE tests contracted for TRICARE East beneficiaries, covering approximately 6 million individuals.
- Increased market access may lead to enhanced revenue opportunities for Exagen.
- None.
SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, MTX and HCQ) will be a contracted covered service with TRICARE East managed care support contractor Humana Military to optimize the care of these patients. The agreement will make AVISE tests available to approximately 6 million beneficiaries.
“We are proud to support the TRICARE East beneficiaries, enabling rheumatologists to improve patient care through the differential diagnosis, prognosis and monitoring of complex autoimmune diseases, including SLE,” said Ron Rocca, President and CEO of Exagen. “Lupus, which is two to three times more prevalent among women of color than among Caucasian women, is an unpredictable and misunderstood disease that ravages different parts of the body. It is difficult to diagnose, hard to live with, a challenge to treat, and can be fatal.”
“We are pleased to offer Exagen as an in-network provider for TRICARE East beneficiaries,” said Brent Densford, President of Humana Military.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune related diseases, including SLE and rheumatoid arthritis. For further information please visit www.exagen.com.
About TRICARE
TRICARE is the health care program for uniformed service members, retirees, and their families around the world. TRICARE provides comprehensive coverage to all 9.5M beneficiaries, including: Health plans, Special programs, Prescriptions, Dental plans, Most TRICARE health plans meet the requirements for minimum essential coverage under the Affordable Care Act. TRICARE is managed by the Defense Health Agency under leadership of the Assistant Secretary of Defense (Health Affairs). For further information please visit https://tricare.mil/About/Facts.
About Humana Military
Humana Military, a wholly-owned subsidiary of Humana Inc., partners with the Department of Defense to administer the TRICARE health program for military members, retirees and their families in the East Region. For more than 20 years, Humana Military has strived to create better health outcomes and simplified experiences for millions of beneficiaries across the United States through TRICARE and other military healthcare programs. High-quality service, cost-effective platforms and progressive approaches to care drive Humana Military to be a thought leader in the industry and an essential partner to the government.
Forward Looking Statements
Exagen cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the expected guidance from the Exagen Scientific Advisory Board, and any potential for increased use of AVISE laboratory tests. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payers and others in the medical community; risks associated with maintaining third-party collaborations such as consulting advisors and Exagen’s performance thereunder; and other risks described in the Company’s prior press releases and in the Company’s filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in the Company’s Registration Statement on Form S-1 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
CONTACTS:
Investors
Westwicke Partners
Mike Cavanaugh
Mike.Cavanaugh@westwicke.com
646.677.1838
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
KAdawi@exagen.com
760.477.5514
FAQ
What is the significance of Exagen's AVISE tests being contracted with TRICARE East?
How many beneficiaries will benefit from Exagen's agreement with TRICARE East?
Which tests are included in Exagen's AVISE offerings now covered by TRICARE East?
What is Exagen Inc.'s stock symbol?
